Company Description
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases.
It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B.
The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.
In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease.
The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
| Country | Netherlands |
| Founded | 1998 |
| IPO Date | Jun 20, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 480 |
| CEO | Matthew Craig Kapusta |
Contact Details
Address: Paasheuvelweg 25a Amsterdam, P7 1105 BP Netherlands | |
| Phone | 1-339-970-7000 |
| Website | uniqure.com |
Stock Details
| Ticker Symbol | QURE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001590560 |
| CUSIP Number | N90064101 |
| ISIN Number | NL0010696654 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Matthew Craig Kapusta | Chief Executive Officer and Executive Director |
| Christian Klemt | Chief Financial Officer, Principal Financial Officer and GM of Amsterdam Site |
| Pierre Caloz | Chief Operating Officer |
| Prof. Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany |
| Richard Porter Ph.D. | Chief Business and Scientific Officer |
| Dr. Jeannette Potts J.D., Ph.D. | Chief Legal and Compliance Officer |
| Dr. Tamara Tugal Ph.D., MBA | Business Development Director |
| Carla Poulson | Interim Chief People and Culture Officer |
| Maria E. Cantor | Chief Corporate Affairs Officer |
| Dr. Amin Abujoub Ph.D. | Chief Quality Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 12, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 12, 2024 | 8-K | Current Report |
| Feb 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 28, 2024 | 8-K | Current Report |
| Feb 28, 2024 | 10-K | Annual Report |
| Feb 26, 2024 | 144 | Filing |
| Feb 26, 2024 | 144 | Filing |
| Feb 26, 2024 | 144 | Filing |